|
PROJECTS
|
|
Adsorbed Vaccines
|
|
Malaria Antigen Vaccines
|
|
Cell Banks
|
|
2E8 Cells
|
|
A549 Master Cell Bank (R)
|
|
BHK-21 Cell Bank
|
|
CHO Cell Bank (R)
|
|
DH5 Alpha E. Coli bank (R)
|
|
HEK293 Master Cell Bank (R)
|
|
K562 Cells
|
|
MRC-5 CELLS
|
|
NS/O Cells
|
|
Vero Cell Bank (R)
|
|
Immunotoxins
|
|
BL-22 (dsFv RFB4-PE38) (Lymphoma)
|
|
ERB-38
|
|
HA-22 (Lymphoma)
|
|
LMB-2 (Anti-TAC Fv PE-38)
|
|
MR1-1 DsFv-PE38
|
|
RN321-RFB4 Onconase
|
|
Monoclonal Antibodies
|
|
11B.11 Rat Anti Murine IL-4
|
|
1D12 Anti-hu IgM
|
|
2A11 Anti Bombesin
|
|
3 Antibodies, Bu12-Saporin, 4KB128-Saporin, OKT10-Saporin
|
|
7G7 Anti-IL-2 alpha R
|
|
95-5-49 Anti T-cell
|
|
95-6-22 Anti T-cell
|
|
Anti CD45RA antibody (Memory T-cell depletion)
|
|
Anti-transferrin scFv
|
|
Ch 14.18 (Neuroblastoma)
|
|
CH EB6 Anti-hu IgA
|
|
Chimeric Antibody Targeting Light Chain- Ch 11-1F4
|
|
D612 Anti Colon Cancer
|
|
HD37
|
|
HeFi-1
|
|
HOKT3 Gamma 1 (ala, ala)
|
|
Hu 14.18 IL-2 Fusion Protein (Neuroblastoma ad Melanoma)
|
|
huATN-658
|
|
Hu B3
|
|
Hu HB22.7
|
|
Hu Mik Beta 1
|
|
huCC49-Delta-CH2 Anti Tag 72
|
|
LEC/NHS76 (PB3)
|
|
MRK-16
|
|
OVB3
|
|
R24 Chimeric
|
|
RFB4
|
|
VH4-34 IgM216
|
|
Natural Products
|
|
cGMP Endotoxin (Challenge Agent)
|
|
Fumagillin
|
|
Geldanamycin
|
|
Staurosporin
|
|
Wortmannin
|
|
Oligonucleotides
|
|
GQ-ODN T40214
|
|
C-myb Antisense OD
|
|
IGF-1R Antisense
|
|
KSR Antisense Oligonucleotide
|
|
STAT-3 Decoy (Head and Neck Cancer)
|
|
Onocolytic Viruses
|
|
Ad 5/3 Delta-24
|
|
Ad5RGDCD/SSTR Oncolytic Virus (Head and Neck Cancer)
|
|
Ad5RGDTK/SSTRTK Oncolytic Virus (Ovarian Cancer)
|
|
Ad-CCL-21
|
|
Adenovirus GM-CSF-CAIX Fusion
|
|
AD-KD3
|
|
AdTSTA-sr39TK
|
|
Delta-24 Adenovirus Control
|
|
Herpes Vector Oncolytic Virus (Glioblastoma)
|
|
MV-NIS
|
|
Polio virus Chimera
|
|
Tissue Specific CRAd: Ad Cox-2 / RGD (Pancreatic Cancer)
|
|
Plasmid Vaccines
|
|
pING-TYRP2
|
|
pNGVL4a-CRT/E7 (detox)
|
|
pNGVL4pNGVL4a - Sig E7 (detox)/HSP70
|
|
Polyvalent Vaccine(JB.SF-HM8) (Melanoma)
|
|
pWRG 1644
|
|
Recombinant Protein
|
|
B7.1 Anti-Her2/neu
|
|
CD40 Ligand
|
|
Cyanovirin HIV Therapy
|
|
Human Recombinant IL-12
|
|
F-5 Cys Anti-Her2/neu scFv AB targeted Liposome
|
|
HPV 16 L2 EbE7 Vaccine with GPI-0100 Adjuvant
|
|
HSP 110 / GP 100 Chaperone
|
|
IL-4 Recertification
|
|
IL-6 Recertification
|
|
Recombinant Wollinella Asparaginase
|
|
rh IGFBP7
|
|
rh IL-15
|
|
rh IL-7 (Renal Cancer)
|
|
rh IL-7 Mammalian
|
|
RTVP-1 Protein
|
|
Transient Expression rh IL-12
|
|
IL-2/Fc and Mutant IL-15/Fc (Type 1 Diabetes)
|
|
F1-V plague Vaccine
|
|
Mutant K-Ras Vaccines
|
|
PA-83 (rPA) Vaccine
|
|
SEB Vaccine
|
|
Synthetic Peptide
|
|
Novel Agent against the MUC1 oncoprotein
|
|
Shepherdin
|
|
Vaccine - Cellular Products
|
|
EBV Supernatant Vaccine
|
|
Master Cell/Working Cell Bank for Allogeneic Vaccine
|
|
Pancreatic Tumor Cell Vaccines (Pancreatic Cancer)
|
|
Phase I/II/III Id Vaccines (Lymphoma)
|
|
Vaccine Peptide
|
|
3 Vaccine Peptides (Breast Cancer)
|
|
Bradykinin Antagonist Peptide
|
|
CAP-1 Peptide Vaccine
|
|
HPV 16-E7 Listeria Vaccine
|
|
HPV E7 Peptide Vaccine
|
|
Khleif Peptide Vaccines
|
|
MART-1 Peptide Vaccine
|
|
Multiple patient specific peptide vaccines
|
|
MVA-CMV (Transplant Medicine)
|
|
PADRE-CMV Vaccine
|
|
PCLUS 3-18MN Peptide
|
|
PR103 (p53-194 His) Vaccine
|
|
PR24 (ras-12 Arg)
|
|
PR26a/p53-282-T-P
|
|
PR-81 Peptide
|
|
PR86/p53-196Pro Peptide
|
|
PR92 (p53-144Arg)
|
|
PR95 (p53-159Pro)
|
|
PXFK Peptide
|
|
V166A-VHL14
|
|
Viral Vaccines
|
|
AFP and GMCSF plasmids (2) and AFP Adenovirus Vaccines
|
|
AFP/GMCSF Adenovirus
|
|
Anaerobic Clostridia Spirogenes Vector
|
|
HSV C134
|
|
VEE Vaccine
|